NCT03444623

Survivin as Predictive Biomarker for RA

Survivin as Predictive Biomarker for Development of Rheumatoid Arthritis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 6,000 (estimated)
• Sponsor: Vastra Gotaland Region · Other Government
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Purpose: to examine the possibility of using the onco-protein survivin as a predictive biomarker for identifying individuals at risk of developing rheumatoid arthritis within a cohort of patients seeking treatment for joint pain/stiffness. Secondly, to study survivin as a prognostic marker for joint destruction, refractory and highly active disease in patients with established RA.

Detailed description

The study will analyse survivin levels in a non-selected material within a cohort of patients seeking help at their primary health care for joint pain, stiffness, swelling etc. Patients presenting with such symptoms (not explained by injury or other factors) are suspected to have an arthritic condition such as RA, and are routinely tested for presence of autoantibodies RF and ACPA. In this observational study we add measurement for survivin to the blood analyses of these patients. Information about patients expressing high levels of survivin will be reported to the referring doctor at the primary health care, and for patients not previously having been examined by a rheumatologist this will be offered. The study will be performed at Sahlgrenska university hospital Gothenburg and Umeå university hospital.

Conditions

• Rheumatoid Arthritis
• Arthralgia
• Joint Pain

Timeline

• Start date: 2013-06-01
• Primary completion: 2023-06-01
• Completion: 2023-12-01
• First posted: 2018-02-23
• Last updated: 2022-05-04

Locations

1 site across 1 country: Sweden